Ivabradine for heart failure

Health Care Comments Off

Ivabradine is now approved for heart failure. EU approval for heart failure [the drug has been licensed for stable angina since 2006] is restricted to specific patients, constituting around 15% of the heart-failure population: those with a heart rate of 75 beats per minute or greater who are in sinus rhythm and who are optimally treated on ACE inhibitors and maximal doses of beta blockers.

The SHIFT study looking at use of ivabradine in heart failure was first reported in 2010. The study noticed the drug was more effective in those with a higher heart rate.

Within that subsection, total mortality is reduced by 17%, heart-failure mortality is down by 39%, and that’s on top of really good ACE-inhibitor (ACEI) and beta-blocker therapy.